# Study of Three Different Schedules of Low-Dose Decitabine in Myelodysplastic Syndrome (MDS)

> **NCT00067808** · PHASE2 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 128 (actual)

## Conditions studied

- Myelodysplastic Syndrome
- Chronic Myelomonocytic Leukemia

## Interventions

- **DRUG:** Decitabine
- **DRUG:** Decitabine
- **DRUG:** Decitabine

## Key facts

- **NCT ID:** NCT00067808
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-10
- **Primary completion:** 2009-05
- **Final completion:** 2009-05
- **Target enrollment:** 128 (ACTUAL)
- **Last updated:** 2012-08-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00067808

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00067808, "Study of Three Different Schedules of Low-Dose Decitabine in Myelodysplastic Syndrome (MDS)". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00067808. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*